123 related articles for article (PubMed ID: 22322837)
1. Predictors of sensitivity to preoperative chemoradiotherapy of rectal adenocarcinoma.
Yan H; Wang R; Zhu K; Zhao W; Jiang S; Feng R; Xu X; Meng X; Sun H; Zhang H; Mu D; Xu Z
Tumori; 2011; 97(6):717-23. PubMed ID: 22322837
[TBL] [Abstract][Full Text] [Related]
2. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of pretreatment carcinoembryonic antigen in patients with rectal cancer receiving preoperative chemoradiotherapy.
Yeo SG; Kim DY; Chang HJ; Park JW; Oh JH; Kim BC; Baek JY; Kim SY; Kim TH
Tumori; 2013; 99(1):93-9. PubMed ID: 23549007
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
Huang D; Lin Q; Song J; Xu B
Dig Surg; 2021; 38(1):24-29. PubMed ID: 33171467
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
6. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
Das P; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Wolff RA; Eng C; Krishnan S; Janjan NA; Crane CH
Cancer; 2007 May; 109(9):1750-5. PubMed ID: 17387743
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant conformal chemoradiation with induction chemotherapy for rectal adenocarcinoma. A prospective observational study.
Fekete Z; Muntean AS; Hica Ş; Rancea A; Resiga L; Csutak C; Todor N; Nagy VM
J Gastrointestin Liver Dis; 2014 Jun; 23(2):171-8. PubMed ID: 24949609
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant-intensified treatment for rectal cancer: time to change?
Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
[TBL] [Abstract][Full Text] [Related]
10. [Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
Lin JZ; Pan ZZ; Zeng ZF; Ding PR; Wan DS
Ai Zheng; 2009 Sep; 28(9):919-22. PubMed ID: 19728907
[TBL] [Abstract][Full Text] [Related]
11. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
[TBL] [Abstract][Full Text] [Related]
13. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
15. Importance of the circumferential extent of tumors and clinical lymph node status as prognostic factors after preoperative chemoradiotherapy and surgery in patients with rectal cancer.
Yoon WS; Park W; Choi DH; Ahn YC; Chun HK; Lee WY; Yun SH; Kang WK; Lim HY; Park YS
Tumori; 2010; 96(4):568-76. PubMed ID: 20968136
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
[TBL] [Abstract][Full Text] [Related]
17. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
Marks EI; Brennan M; El-Deiry WS
Cancer Biol Ther; 2015; 16(8):1136-9. PubMed ID: 26047368
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
Wang CC; Liang JT; Tsai CL; Chen YH; Lin YL; Shun CT; Cheng JC
World J Surg Oncol; 2014 Nov; 12():329. PubMed ID: 25373828
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery.
Yang KL; Yang SH; Liang WY; Kuo YJ; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC; Chu LS; Wang LW
Radiat Oncol; 2013 Mar; 8():43. PubMed ID: 23452434
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
